All In Biotech

Drug Trial Radar · NCT05365581

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 398 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

398

Planned (sponsor's estimate)

Start

Jun 7, 2022

Primary completion

May 31, 2028

Study completion May 31, 2028

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
May 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. GEJ is where the tube that carries food (esophagus) joins the stomach. Before ASP2138 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. In this study, ASP2138 will either be given by itself, or given together with standard treatments for gastric, GEJ and pancreatic cancer. Pembrolizumab and mFOLFOX6, and ramucirumab and paclitaxel are standard treatments for gastric and GEJ cancer. mFOLFIRINOX is a standard treatment for pancreatic cancer. This information will help find a suitable dose of ASP2138 given by itself and together with the standard cancer treatments and to check for potential medical problems from the treatments. The main aims of the study are: * To check the safety of ASP2138 and how well people can tolerate medical problems during the study. * To find a suitable dose of ASP2138 to be used later in the study. * These are done for ASP2138 given by itself and when given together with the standard cancer treatments. Adults 18 years or older with stomach cancer, GEJ cancer, or pancreatic cancer can take part. Their cancer is locally advanced unresectable or metastatic. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. There should also be the CLDN18.2 marker in a tumor sample. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers, have specific infections, have a condition such as hemophagocytic lymphohistiocytosis (HLH) which is when the body over-reacts to a "trigger" such as infection, or have a specific heart condition ("New York Heart Association Class III or IV"). Phase 1: Lower to higher doses of ASP2138 * ASP2138 is either given through a vein (intravenous infusion) or just under the skin (subcutaneous injection). * Different small groups are given lower to higher doses of ASAP2138. * ASP2138 is either given by itself, or given with 1 of 3 standard treatments: * Pembrolizumab and mFOLFOX6 (first treatment for gastric GEJ cancer) * Ramacirumab and paclitaxel (Second treatment for gastric or GEJ cancer) * ASP2138 with mFOLFIRINOX (first treatment for pancreatic cancer) Phase 1b: doses of ASP2138 worked out from Phase 1 * ASP2138 is either given through a vein or just under the skin. This depends on the findings from Phase 1. * People with gastric cancer, GEJ cancer or pancreatic cancer are given doses of ASP2138, worked out from Phase 1. * This includes doses of ASP2138 given by itself and ASP2138 given with the standard cancer treatments. * The standard cancer treatments given depends on the type of cancer they have. End of treatment visit: This is 7 days after final dose of study treatment or if the study doctor decides to stop the person's treatment. People who have locally advanced unresectable pancreatic cancer will not receive ASP2138 by itself.

Conditions

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Pancreatic Adenocarcinoma

Interventions

  • ASP2138Drug

    Intravenously or Subcutaneously

  • PembrolizumabDrug

    Intravenously

  • OxaliplatinDrug

    Intravenously

  • LeucovorinDrug

    Intravenously

  • FluorouracilDrug

    Intravenously

  • RamucirumabDrug

    Intravenously

  • PaclitaxelDrug

    Intravenously

  • IrinotecanDrug

    Intravenously

  • CapecitabineDrug

    Oral Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Dose Escalation)Time frame: Up to 28 days
  2. Number of participants with Adverse Events (AEs)Time frame: Up to 27 months
  3. Number of participants with serious AEs (SAEs)Time frame: Up to 27 months
  4. Number of participants with laboratory value abnormalitiesTime frame: Up to 25 months
  5. Number of participants with vital sign abnormalitiesTime frame: Up to 27 months
  6. Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: Up to 24 months
  7. Number of participants with physical exam abnormalitiesTime frame: Up to 25 months
  8. Number of participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to 25 months

Locations

46 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California Irvine Medical Center

    Orange, California · Recruiting

  • UCLA Dept of Medicine - Hematology/Oncology, Santa Monica

    Santa Monica, California · Withdrawn

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Completed

  • NYU Langone Medical Center - NYU Medical Oncology Associates

    New York, New York · Recruiting

  • Columbia University

    New York, New York · Completed

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke Children's Hospital and Health Center

    Durham, North Carolina · Recruiting

  • Wake Forest University Baptist Health

    Winston-Salem, North Carolina · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Recruiting

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

  • Site FR33003

    Lyon, France · Recruiting

  • Site FR33004

    Marseille, France · Recruiting

  • Site FR33006

    Poitiers, France · Recruiting

  • Site FR33001

    Saint-Herblain, France · Recruiting

  • Site FR33002

    Toulouse, France · Recruiting

  • Site FR33005

    Vaillant, Villejuif, France · Recruiting

  • Site IT39004

    Milan, Italy · Recruiting

  • Site IT39001

    Milan, Italy · Recruiting

  • Site IT39005

    Rozzano, Italy · Recruiting

  • Site IT39003

    Verona, Italy · Recruiting

  • Aichi Cancer Center

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan · Recruiting

  • Kindai University Hospital

    Sakai, Osaka, Japan · Recruiting

  • The University of Osaka Hospital

    Suita, Osaka, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Completed

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Koto-ku, Tokyo, Japan · Recruiting

  • PanOncology Trials

    San Juan, Puerto Rico · Recruiting

  • Site KR82004

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Site KR82001

    Guro-gu, Seoul, South Korea · Recruiting

  • Site KR82002

    Jongno-gu, Seoul, South Korea · Recruiting

  • Site KR82003

    Seocho-gu, Seoul, South Korea · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.